The effect of neurohormonal antagonists in reducing heart failure hospitalizations

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 139-150

  Williams, Randall E ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Midwest Heart Specialists   (United States)

Author keywords

Adrenergic system; Clinical trials; Disease management programs; Heart failure; Hospitalizations; Patient registries; Renin angiotensin aldosterone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; METOPROLOL; NEUROHORMONE; SPIRONOLACTONE; VALSARTAN;

ACCURACY; ADRENERGIC SYSTEM; CLINICAL TRIAL; COST OF ILLNESS; DRUG COST; DRUG EFFECT; DRUG MECHANISM; DRUG USE; EVALUATION; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; LENGTH OF STAY; MANAGED CARE; MEDICAL LITERATURE; MEDLINE; MONEY; PERFORMANCE; PUBLICATION; REGISTER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; CARDIAC OUTPUT, LOW; HOSPITALIZATION; HUMANS; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 30844466642     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80233     Document Type: Review

References (65)

1. American Heart Association Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX, 2005
2. Rich MW. Heart failure disease management: a critical review. J Card Fail 1999;5:64-75
3. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A-38A
4. Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs [US Carvedilol Heart Failure Study Group]. J Am Coll Cardiol 2001;37:1692-9
5. Rich MW. Management of heart failure in the elderly. Heart Fail Rev 2002;7:89-97
6. Xuan J, Duong PT, Russo PA, Lacey MJ, Wong B. The economic burden of congestive heart failure in a managed care population. Am J Manag Care 2000;6:693-700
7. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
8. Connelly CM, McLaughlin RJ, Vogel WM, Apstein CS. Reversible and irreversible elongation of ischemic, infarcted, and healed myocardium in response to increases in preload and afterload. Circulation 1991;84:387-99
9. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol 1992;20:248-54
10. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure [Results of a Veterans Administration Cooperative Study]. New Engl J Med 1986;314:1547-52
11. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. New Engl J Med 1991;325:303-10
12. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22
13. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6
14. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41:39-52
15. Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 2002;34:1435-42
16. Struthers AD. Aldosterone: an important mediator of cardiac remodelling in heart failure. Br J Cardiol 2005;12:211-8
17. Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure [The V-HeFT VA Cooperative Studies Group]. Circulation 1993;87:VI78-VI87
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New Engl J Med. 1991;325:293-302
19. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. J Am Med Assoc 1988;259:539-44
20. Pocock S, Wang D, Wilhelmsen L, Hennekens CH. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J 2005;149:939-43
21. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New Engl J Med 2001;345:1667-75
22. Anon. V-HeFT positive for enalapril. Br J Hosp Med 1991;45:233
23. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66
24. Heart Failure Society of America. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - pharmacological approaches. J Card Fail 1999;5:357-82
25. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998;19:1552-63
26. Cicoira M, Zanolla L, Franceschini L, et al. Relation of aldosterone 'escape' despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002;89:403-7
27. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure [Randomized Aldactone Evaluation Study Investigators]. New Engl J Med 1999;341:709-17
28. Keating GM, Plosker GL. Eplerenone: a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. Drugs 2004;64:2689-707
29. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003;348:1309-21
30. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984;311:819-23
31. Packer M. Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. Eur Heart J 1998;19(Suppl B):B40-B46
32. Prakash A, Markham A. Metoprolol: a review of its use in chronic heart failure. Drugs 2000;60:647-78
33. McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs 2002;62:2677-96
34. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17 (Suppl B):8-16
35. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87
36. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure [US Carvedilol Heart Failure Study Group]. New Engl J Med 1996;334:1349-55
37. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure [US Carvedilol Heart Failure Study Group]. Circulation 1996;94:2800-6
38. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
39. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7
40. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [MERIT-HF Study Group]. J Am Med Assoc 2000;283:1295-302
41. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651-8
42. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194-9
43. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. J Am Med Assoc 2003;289:712-8
44. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13
45. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the beta 1-receptor? [A perspective on the results of the COMET Trial]. J Card Fail 2003;9:429
46. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [MOCHA Investigators]. Circulation 1996;94:2807-16
47. Luzier AB, Antell LA, Chang LL, Xuan J, Roth DA. Reimbursement claims analysis of outcomes with carvedilol and metoprolol. Ann Pharmacother 2002;36:386-91
48. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16
49. Gomberg-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. Arch Intern Med 2001;161:342-52
50. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Overview of the Heart Failure (HF) Core Measure Set by Joint Commission on Accreditation of Healthcare Organizations. Available at: http://www.jcaho.org/ pms/ core+measures/hf_overview.htm [accessed September 9, 2005]
51. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001 [published correction appears in J Am Med Assoc 2003;289:2649]. J Am Med Assoc 2003;289:305-12
52. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation 2001;103:2768-70
53. Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med 2002;3(Suppl 3):S2-S10
54. Taylor CB, Houston-Miller N, Killen JD, DeBusk RF. Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention. Ann Intern Med 1990;113:118-23
55. Gattis WA, O'Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol 2004;93:74-6
56. Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001;110(Suppl 7A):74S-80S
57. Delea TE, Stanford R, Hagiwara M, Edelsberg JS, Oster G. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. Int J Cardiol 2005;99:117-24
58. Franciosa JA, Massie BM, Lukas MA, et al. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J 2004;148:718-26
59. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004;148:43-51
60. Fonarow G, Abraham WT, Albert N, et al. Impact of evidence-based heart failure therapy use at hospital discharge on treatment rates during follow-up: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2005;45:345A
61. Ramahi TM, Longo MD, Rohlfs K, Sheynberg N. Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. Clin Cardiol 2000;23:909-14
62. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-84
63. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997;30:725-32
64. Rich MW, Gray DB, Beckham V, Wittenberg C, Luther P. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. Am J Med 1996;101:270-6
65. Ansari M, Shilpak MG, Heindenreich PA, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation 2003;107:2799-804